We are live on ! Find out more
NKGN

NKGen Biotech, Inc. Common Stock
NKGN

Delisted

NKGN was delisted on the 4th of March, 2025.

Back to rankings

41 hedge funds and large institutions have $109M invested in NKGen Biotech, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

18% more capital invested

Capital invested by funds: $92.1M → $109M (+$16.7M)

11% more funds holding

Funds holding: 37 → 41 (+4)

Holders
41
Holders Change
+4
Holders Change %
+10.81%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
6
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PC
Periscope Capital
Ontario, Canada
+$5.83M
2
KC
Kepos Capital
New York
+$5.11M
3
CFIA
Cantor Fitzgerald Investment Advisors
New York
+$2.48M
4
HIH
HRS Investment Holdings
New York
+$2.48M
5
CSS
Cubist Systematic Strategies
Connecticut
+$1.7M

Top Sellers

Rank Fund Capital Flow
1
AA
AQR Arbitrage
Connecticut
-$2.67M
2
AIMCA
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
-$1.94M
3
JG
Jefferies Group
New York
-$1.7M
4
OCM
Oaktree Capital Management
California
-$486K
5
EIP
Easterly Investment Partners
Massachusetts
-$485K
Name Holding Trade Value Shares
Change 		Change in
Stake
CL
26
CSS LLC
Illinois
$980K +$984K +101,103 New
GF
27
Gabelli Funds
New York
$970K – – –
SC
28
Sculptor Capital
New York
$969K – – –
OCM
29
Oaktree Capital Management
California
$967K -$486K -50,000 -33%
VCIM
30
Velan Capital Investment Management
Georgia
$836K +$842K +86,506 New
GCIA
31
Gabelli & Co Investment Advisers
New York
$833K – – –
EAM
32
Exos Asset Management
New York
$678K – – –
Marshall Wace
33
Marshall Wace
United Kingdom
$523K +$34.6K +3,552 +7%
TI
34
Telemetry Investments
New York
$518K -$3.89K -400 -0.7%
SSA
35
Schonfeld Strategic Advisors
New York
$484K +$346K +35,549 +246%
Walleye Capital
36
Walleye Capital
New York
$431K -$77.3K -7,948 -15%
Walleye Trading
37
Walleye Trading
New York
$349K – – –
HighTower Advisors
38
HighTower Advisors
Illinois
$317K -$9.73K -1,000 -3%
FBCM
39
Fort Baker Capital Management
California
$240K – – –
AA
40
AQR Arbitrage
Connecticut
$126K -$2.67M -274,640 -95%
JP Morgan Chase
41
JP Morgan Chase
New York
$80K – – –
AIMCA
42
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
– -$1.94M -200,000 Closed
JG
43
Jefferies Group
New York
– -$1.7M -175,000 Closed
EIP
44
Easterly Investment Partners
Massachusetts
– -$485K -50,000 Closed
1
2

NKGN Hedge Fund Activity: Q4 2021 in Review

41 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q4 2021, worth a combined $109M — up 18% from $92.1M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new NKGN positions and 3 closed out — a net gain of 4 holders — while 6 added to existing stakes and 5 trimmed.

The largest buyer was Periscope Capital, opening a new position worth an estimated $5.83M. The largest seller was AQR Arbitrage, cutting an estimated $2.67M.

  • 41 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q4 2021, up from 37 in Q3 2021.
  • Funds reported $109M of NKGen Biotech, Inc. Common Stock stock for Q4 2021, up 18% quarter-over-quarter.
  • 7 funds opened new NKGen Biotech, Inc. Common Stock positions in Q4 2021 and 3 closed out, a net change of +4 holders.
  • The largest NKGen Biotech, Inc. Common Stock buyer in Q4 2021 was Periscope Capital, an estimated $5.83M added.
  • The largest NKGen Biotech, Inc. Common Stock seller in Q4 2021 was AQR Arbitrage, an estimated $2.67M sold.

Based on aggregated 13F filings for Q4 2021.